This trial is active, not recruiting.

Condition dementia
Treatment far infrared
Phase phase 1
Sponsor GAAD Medical Research Institute Inc.
Start date February 2008
End date January 2009
Trial size 4 participants
Trial identifier NCT00574054, GAAD-DEM-CTP1


This trial is a preliminary study to determine the use of far infrared radiation for the treatment of dementia and other mental sickness.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
far infrared
Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.

Primary Outcomes

The primary end point is to determine the therapeutic effects of far infrared radiation on dementia.
time frame: 1 year

Secondary Outcomes

The secondary end point of the study is to evaluate the therapeutic effects of far infrared radiation on other related mental illness including Alzheimer's, multiple sclerosis and stroke rehabilitation.
time frame: 1 year

Eligibility Criteria

Male or female participants at least 2 years old.

Inclusion Criteria: - Persons age 2 or older, with dementia, Alzheimer's, Huntington's disease, Parkinson's disease, Down's syndrome, multiple sclerosis or stroke Exclusion Criteria: - Persons with severe mental illness that are confined to mental hospitals etc., as defined by the USA Diagnostic and Statistical Manual of Mental Disorders (DSM)

Additional Information

Official title Phase 1 Study to Evaluate the Efficacy of Using Energy Specific Far Infrared Radiation Treatment for Dementia and Other Related Mental Illness.
Principal investigator Kwasi Donyina, Ph.D.
Description Dementia is the progressive decline in cognitive function due to damage or disease in the brain beyond what might be expected from normal aging. Particularly affected areas include memory, attention, language, and problem solving. Especially in the later stages of the condition, affected persons may be disoriented in place and in person (not knowing who they are). The prevalence of dementia is rising as the global life expectancy is rising. Particularly in Western countries, there is increasing concern about the economic impact that dementia will have in future, older populaces. It is a disease that is strongly associated with age; 1% of those aged 60-65, 6% of those aged 75-79, and 45% of those aged 95 or older suffer from the disease. We are postulating that the use of far infrared radiation on the central nervous system, the endocrine system and the viscera will have a positive effect on treating dementia and other neurological illnesses.
Trial information was received from ClinicalTrials.gov and was last updated in August 2009.
Information provided to ClinicalTrials.gov by GAAD Medical Research Institute Inc..